

e-Therapeutics plc

(“e-Therapeutics” or the “Company”)

Notification of Director’s and Significant Shareholders’ Interests

e-Therapeutics has been notified today that RAB Special Situations (Master) Fund Limited (“RAB”) granted options over 1,250,000 of its ordinary shares of 0.1 pence each in the capital of the Company (“Ordinary Shares”) to Cornhill on 30 November 2007. These options are exercisable at 67 pence per Ordinary Share from 30 November 2007 until 28 November 2009. Any exercise of the options during the period until 28 November 2008 is subject to the consent of WH Ireland, the Company’s nominated adviser. RAB is currently the beneficial owner of 17,407,950 Ordinary Shares, representing 31.25% of the issued Ordinary Share capital of the Company.

e-Therapeutics has also been notified today that Malcolm Young, chief executive, has today granted options over 500,000 of his Ordinary Shares to Cornhill Asset Management Limited (“Cornhill”), the Company’s broker. These options are exercisable at 67 pence per Ordinary Share from 3 December 2008 until 3 December 2011. Any exercise of the options during the period from 3 December 2008 until 28 November 2009 is subject to the consent of WH Ireland, the Company’s nominated adviser. Malcolm Young currently holds 20,620,482 Ordinary Shares, representing 37.01% of the issued Ordinary Share capital of the Company.

Following the grant of the options as set out above, Cornhill has an interest in the securities of e-Therapeutics as follows:

	Number
Options to subscribe for Ordinary Shares (as set out above)	1,750,000
Warrants to subscribe for Ordinary Shares	60,000

For more information please contact:

John Cordiner, e-Therapeutics plc	Tel: 0191 233 1317
Richard Lindley, WH Ireland Limited	Tel: 0113 394 6628